Accounts Payable

9 Months Ended

Sep. 30, 2020

Accounts Payable

Accounts Payable

5.            Accounts Payable

As of September 30, 2020, current liabilities included accounts payable of $0.6 million, comprised primarily of amounts owed to the Company's clinical research organization for its clinical trials for prexigebersen in AML, BP1002 in lymphoma and prexigebersen-A in solid tumors of $0.4 million and legal and patent fees of $0.2 million. As of December 31, 2019, current liabilities included accounts payable of $0.5 million, comprised primarily of amounts owed for external research expenses related to manufacturing costs of $0.3 million and legal and patent fees of $0.2 million.